Shenzhen BinDeBio Ltd.
CAR-T cell immunotherapy(Shenzhen BinDeBio Ltd.)은 GD2 표적 세포·유전자 치료로, B-cell Acute Lymphoblastic Leukemia; Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: CAR-T cell functionality required genetic ablation of STING in CAR-T cells and was dependent on cancer cell-intrinsic STING signaling on STING-agonistic treatment. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 80.3% (ClinicalTrials.gov NCT03483103). 차별점: novel mechanism by which MT nanoparticles enhance the proliferation, and thus the cytotoxicity of PDGFRβ CAR-T cells by.
GD2
B-cell Acute Lymphoblastic Leukemia; Lymphoma
Active
CAR-T cell function for additive therapy against liver fibrosis
may
humanized mouse model
novel mechanism by which MT nanoparticles enhance the proliferation, and thus the cytotoxicity of PDGFRβ CAR-T cells by
CAR-T cell functionality required genetic ablation of STING in CAR-T cells and was dependent on cancer cell-intrinsic STING signaling on STING-agonistic treatment
cytokine release syndrome (CRS), and progression-free survival (PFS) were evaluated
payload may vary depending on tumor type, target antigen expression level, and microenvironmental context, making systematic ex
biomarker that may help individualized risk stratification and inform treatment optimization in CAR-T therapy
resistance to dominant suppressive pathways such as TGF-β and adenosine signalling, improved trafficking and tissue penetration
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Shenzhen BinDeBio Ltd.
CAR-T cell immunotherapy(Shenzhen BinDeBio Ltd.)은 GD2 표적 세포·유전자 치료로, B-cell Acute Lymphoblastic Leukemia; Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: CAR-T cell functionality required genetic ablation of STING in CAR-T cells and was dependent on cancer cell-intrinsic STING signaling on STING-agonistic treatment. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 80.3% (ClinicalTrials.gov NCT03483103). 차별점: novel mechanism by which MT nanoparticles enhance the proliferation, and thus the cytotoxicity of PDGFRβ CAR-T cells by.
GD2
B-cell Acute Lymphoblastic Leukemia; Lymphoma
Active
CAR-T cell function for additive therapy against liver fibrosis
may
humanized mouse model
novel mechanism by which MT nanoparticles enhance the proliferation, and thus the cytotoxicity of PDGFRβ CAR-T cells by
CAR-T cell functionality required genetic ablation of STING in CAR-T cells and was dependent on cancer cell-intrinsic STING signaling on STING-agonistic treatment
cytokine release syndrome (CRS), and progression-free survival (PFS) were evaluated
payload may vary depending on tumor type, target antigen expression level, and microenvironmental context, making systematic ex
biomarker that may help individualized risk stratification and inform treatment optimization in CAR-T therapy
resistance to dominant suppressive pathways such as TGF-β and adenosine signalling, improved trafficking and tissue penetration
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.